Search Results

April is the month of DNA Day, a special day commemorating the discovery of the DNA double helix structure GPCR-targeted drugs, and the exploration of GPCRs as key regulators of physiological processes and therapeutic microscopy, have allowed us to understand the structural dynamics during receptor activation. drug discovery and design targeting GPCRs, leading to the development of novel therapeutics. Structural bioinformatics analysis of variants on GPCR function.

These receptors respond to a variety of signals by undergoing structural changes that activate internal Twenty transition structures generated from overlapping particle subsets along this pathway provide a From the initial GTP binding, the structures highlight critical shifts in the α5 helix and the α-helical Concurrently, the α1 helix extends, propagating structural changes throughout the G protein. puzzles and underscores the importance of understanding cellular processes at the molecular level for therapeutic

GPCR Partner, Domain Therapeutics, for their nomination of the best-in-class CCR8 antibody candidate, History and function of the lactate receptor GPR81/HCAR1 in the brain: a putative therapeutic target G protein-coupled receptors as targets for transformative neuropsychiatric therapeutics. Structural and Molecular Insights into GPCR Function Identification of a potential structure-based GPCR Domain Therapeutics announces nomination of best-in-class CCR8 antibody candidate, DT-7012, further strengthening

the development of more selective drugs capable of modulating specific signaling pathways, improving therapeutic This allows for tailoring the half-life of nanobodies to increase their therapeutic window depending its conformation, protects the Schiff base, and prevents protein degradation, potentially offering therapeutic Nanobodies: A Review of Generation, Diagnostics and Therapeutics. Structural biology.

appreciate the incredible versatility of GPCRs and how small molecules can affect their behavior for therapeutic Learn how to therapeutically exploit GPCRs (Physiology’s ‘Swiss Army Knife’) vast repertoire of ways Adjust ligand kinetics and tissue disposition for optimal therapeutic activity. and Molecular Insights into GPCR Function Structural insights into KSHV-GPCR constitutive activation Structural basis of μ-opioid receptor targeting by a nanobody antagonist Probing the energy landscape

GPCR Symposium on Structural and Molecular Insights on GPCR Activation! GPCRs in Cardiology, Endocrinology, and Taste Clinical, Pathophysiologic, Genetic, and Therapeutic Progress Structural basis for the ubiquitination of G protein βγ subunits by KCTD5/Cullin3 E3 ligase. Secures $150 Million in Series B Financing to Advance Pipeline of Novel GPCR-targeted Medicines OMass Therapeutics Directors Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Confo Therapeutics

Adhesion GPCRs A correlation study of adhesion G protein-coupled receptors as potential therapeutic targets and Molecular Insights into GPCR Function Structural basis for recognition of 26RFa by the pyroglutamylated Industry News NanoImaging Services and Cube Biotech Collaborate to Enhance Cryo-EM Enabled Gene to Structure Workflow Domain Therapeutics Strengthens Its Intellectual Property for Its Series of Treg Depleting ACTH-Dependent Cushing’s Syndrome (ADCS) Septerna Presents Preclinical Data at ENDO 2024 Highlighting Therapeutic

Graeme Milligan and their colleagues research on Pro-phagocytic function and structural basis of GPR84 Kevin Wright on his new position as Director of Targeted and Immuno-oncology at GPCR Therapeutics, our GPCR Symposium on 'GPCRs as Therapeutic Modalities' with Richa Tyagi, Dr. Terry Kenakin, Dr. Kevin Wright Joins GPCR Therapeutics as Director of Targeted and Immuno-oncology Sosei Heptares Adds Lefkowitz's Career at Duke October 3, 2023, | FREE Seminar: Changing paradigm on Therapeutics targeting

The paper explores: Detection and quantification of signaling bias Influence of biased signaling on therapeutic Terry’s Pharmacology Corner provides a structured environment to maintain interpretive discipline: Weekly If you want structured, year-round access to Terry’s full library — including advanced lectures, archived

GPCR Symposium on 'GPCRs as Therapeutic Modalities' Showcase your project with a 1-minute abstract video Bolsters Leadership Team as the Company Advances its Multi-Product Pipeline Toward Clinical Studies Confo Therapeutics 21st Annual Global Healthcare Conference CEO Raymond Stevens to Speak at STAT Future Summit on Obesity Therapeutics Function and Biased Signaling" at the DOT NEW October 3, 2023 | FREE Seminar: Changing paradigm on Therapeutics and Exhibition June 2 - 4, 2024 | Chemotactic Cytokines GPCR Jobs Researcher / Senior Researcher in Structural

Bryan Roth and Brian Krumm for their study on Molecular glues as potential GPCR therapeutics Drs. breast cancer progression by suppressing the MMP8-mediated antitumorigenic effects GPR56: A potential therapeutic Dynamics Structural insights into ligand recognition and activation of the succinate receptor SUCNR1 via site-selective activation of mTOR GPCR Binders, Drugs, and more Molecular glues as potential GPCR therapeutics and Molecular Insights into GPCR Function Structural basis for hormone recognition and distinctive Gq

Rovati , Valerie Capra , Caroline M Gorvin , Alexander S Hauser Calcineurin-fusion facilitates cryo-EM structure Nxera Pharma Teams to Unleash Machine Learning on Elusive Biological Keys to Medical Therapies From Structure to Solution: How Structural Biology Informs the Development of Drugs Targeting G Protein-Coupled Receptors ARTICA THERAPEUTICS ANNOUNCES ESTABLISHMENT OF SCIENTIFIC ADVISORY BOARD GPCR Events, Meetings, and GPCR Jobs NEW GPCR Molecular Pharmacologist Scientist - Biology Scientist I Cell Biology - Tectonic Therapeutic

GPCR Partner, GPCR Therapeutics, for passing the Technology Evaluation process for listing on the KOSDAQ GPCR Symposium on Structural and Molecular Insights on GPCR Activation. Structural and Molecular Insights into GPCR Function Structure-Activity Relationship Study of the High-Affinity GPCR Therapeutics passes the Technology Evaluation process for listing on KOSDAQ. function" (June 28 - 30, 2023) FREE Seminar Antibodies targeting Membrane Proteins - From Antigen to New Therapeutics

. 👉 The problem begins when ambition grows faster than structure. A strong preclinical signal opens adjacent therapeutic areas. It means structuring how that vision unfolds over time . 👉 The strongest biotech leaders understand They structure it. It fuels platforms, pipelines, and long-term vision. 👉 But ambition without structure creates drift

September 5th to 26th, 2024 Overview: GPCRs have been and arguably still are the most prolific and fertile therapeutic trade-offs in whitefly G protein-coupled receptor kinases in hypertension: physiology, pathogenesis, and therapeutic proteins block the internalization of cognate GPCRs and disrupt downstream intracellular signaling Therapeutic acute and chronic relaxin-3 receptor (RXFP3) activation in the rat retrosplenial cortex Unveiling the therapeutic Cryo-EM advances in GPCR structure determination GPCR-G protein selectivity revealed by structural pharmacology

Arm's Race' Developments Five protein-design questions that still challenge AI Prix Galien USA: Domain Therapeutics Nominated for the Prestigious Best Startup Award Tectonic Therapeutic Announces Positive Phase 1a Results 2024 January 13 - 16, 2025 | PepTalk 2025 January 25 - 29, 2025 | SLAS 2025 February 15 - 16, 2025 | Structural 20th World Congress of Basic and Clinical Pharmacology GPCR Jobs Scientist I Cell Biology - Tectonic Therapeutic Hauser Group Postdoctoral Scholar – iPSC in cardiac and endothelial cell function Protein Biochemist/Structural

Xavier Leroy for his new role as CEO of GIO Therapeutics Dr. and Molecular Insights into GPCR Function Structural insights into membrane adenylyl cyclases, initiators Molecular mechanism of GPCR spatial organization at the plasma membrane Industry News Launch of GIO Therapeutics , founded by Cumulus Oncology, to develop therapeutics targeting G protein-coupled receptors to treat cancer and inflammation AVROBIO and Tectonic Therapeutic Announce Merger Trevena Inc Elevates Barry

Japan Awards 2024 GPCR therapies: Eight promising biotechs hacking the cell signaling pathway From Structure to Solution: How Structural Biology Informs the Development of Drugs Targeting G Protein-Coupled Receptors 20th World Congress of Basic and Clinical Pharmacology GPCR Jobs Scientist I Cell Biology - Tectonic Therapeutic Hauser Group Postdoctoral Scholar – iPSC in cardiac and endothelial cell function Protein Biochemist/Structural correction of heterozygous mutation in exon 6 of the CaSR gene Reviews, GPCRs, and more Insight into structural

This week's highlights: Driving Pharma Innovation in Oncology: Domain Therapeutics' Success Proven by GPCR Symposium on GPCRs as Therapeutic Modalities is on September 22nd. Structural and Molecular Insights into GPCR Function Ternary model structural complex of C5a, C5aR2, Industry News Omass Therapeutics Celebrates a Series of Recent Publications by their Scientists. Discover a New Way To Develop Drugs Without Side Effects Driving Pharma Innovation in Oncology: Domain Therapeutics

GPCRs in Oncology and Immunology Expanding role of CXCR2 and therapeutic potential of CXCR2 antagonists Reviews, GPCRs, and more The leukotriene B4 receptors BLT1 and BLT2 as potential therapeutic targets. Structural and Molecular Insights into GPCR Function Structural basis of selective cannabinoid CB2 receptor It Will Participate For H1 2023 Learn more about Exscientia new pipeline candidate, EXS74539 Domain Therapeutics women-men professional equality index Octant introduces Hypatia, their New Robotic Drug Hunter GPCR Therapeutics

Through structured lectures, monthly live AMAs, and full replay access, the Corner provides ongoing refinement know the pressure of distinguishing between orthosteric and allosteric drug mechanisms—especially when structural dependence reveals hidden selectivity and efficacy shifts It becomes critical in both screening strategy and therapeutic Habits for Data Quality and Reproducibility Detection assays identify activity; they do not validate therapeutic Terry’s Pharmacology Corner provides a structured environment for that evolution: Weekly advanced pharmacology

Kooistra ,   David E Gloriam ,   Alexander S Hauser GPCRdb in 2025: adding odorant receptors, data mapper, structure Georgios Skiniotis as Director of the New Center of Excellence for Structural Cell Biology Monash Scholars 2025 Milestones Recursion and Exscientia have merged to enhance drug discovery GPCR Classes Pathios Therapeutics 2024 January 13 - 16, 2025 | PepTalk 2025 January 25 - 29, 2025 | SLAS 2025 February 15 - 16, 2025 | Structural Basic and Clinical Pharmacology GPCR Jobs NEW Scientist - Biology Scientist I Cell Biology - Tectonic Therapeutic

week:  nanomedicines targeting PAR2 for sustained analgesia; Emerging Voices in GPCR Biology; Domain Therapeutics Must-read publications:  AT1R β-arrestin bias; UII receptor structure; β2AR constant-pH dynamics. Jens Carlsson shares how structure-based design, molecular dynamics, and smart collaboration turn models Value at a glance: From screens to hits —how to identify novel GPCR ligands with structure-based workflows Staying current is essential as kinetics, structure, and signaling evolve rapidly.

Recent advances in structural biology and pharmacology have revealed the existence of allosteric sites other GPCR-regulated systems such as free fatty acid receptors (FFARs), now regarded as targets for therapeutic and β-arrestin coupling, enabling the development of biased agonists and antagonists with distinct therapeutic Allosteric modulation is gaining prominence in GPCR therapeutics, with the discovery of an intracellular Biased allosteric modulators can enhance the safety and efficacy of GPCR-targeted therapeutics by selectively

GPCR Symposium on 'GPCRs as Therapeutic Modalities'. neutrophil chemoattractant Neuroimmune interplay during type 2 inflammation: symptoms, mechanisms and therapeutic and Molecular Insights into GPCR Function Structural bioinformatics studies of bacterial outer membrane beta-barrel transporters and their AlphaFold2 predicted water-soluble QTY variants Structural basis Launches with $33 Million Seed Round to Fuel its Drug Discovery Engine and Pipeline of Small Molecule Therapeutics

receptor subfamily, CX3CR1 binds to its sole endogenous ligand CX3CL1, which shows notable potential as a therapeutic However, the drug development of CX3CR1 is hampered partially by the lack of structural information. Here, we present two cryo-electron microscopy structures of CX3CR1-Gi1 complexes in ligand-free and CX3CL1 Together with functional data, the structures reveal the key factors that govern the recognition of CX3CL1 smaller conformational change of helix VI upon activation than previously solved class A GPCR-Gi complex structures

Structure-guided design of a peripherally restricted chemogenetic system Hye Jin Kang , Brian E Krumm 2024 January 13 - 16, 2025 | PepTalk 2025 January 25 - 29, 2025 | SLAS 2025 February 15 - 16, 2025 | Structural Pharmacology GPCR Jobs GPCR Molecular Pharmacologist Scientist - Biology Scientist I Cell Biology - Tectonic Therapeutic Hauser Group Postdoctoral Scholar – iPSC in cardiac and endothelial cell function Protein Biochemist/Structural design of a peripherally restricted chemogenetic system Structural and Molecular Insights into GPCR

Xavier Leroy on his appointment as CEO of GIO Therapeutics! Congratulations to Domain Therapeutics for being awarded the RHU SPRINT consortium grant. Endocrinology, and Taste The Role of Gut Microbiota and Associated Compounds in Cardiovascular Health and its Therapeutic Living Cells with Cucurbit[7]uril and Hemicyanine as a "Turn-On" Fluorescence Probe Industry News Domain Therapeutics Xavier Leroy appointed as CEO of GIO Therapeutics GPCR Events, Meetings, and Webinars NOW!

GPCR Symposium about 'GPCRs as Therapeutic Modalities' rocked it! , and function of 5-HTR1E serotonin receptor Structural and Molecular Insights into GPCR Function Cryo-EM structures of human GPR34 enable the identification of selective antagonists Industry News Inside the recommended by NICE for acute migraines Addex mGlu2 NAM Cognition Program Receives €4 Million Grant Confo Therapeutics Lefkowitz's Career at Duke October 3, 2023, | FREE Seminar: Changing paradigm on Therapeutics targeting

Congrats to the GPCR Therapeutics team for their recent paper in the American College of Clinical Pharmacology GPCR Symposium on 'GPCRs as Therapeutic Modalities'. and Molecular Insights into GPCR Function A method for structure determination of GPCRs in various states and oligomerization Molecular Insights into GPCR Mechanisms for Drugs of Abuse Industry News 'GPCR Therapeutics Nordisk to Acquire Inversago Pharma GPCR Events, Meetings, and Webinars NEW Antiverse: Reimagining Therapeutic